IFNB1 and myeloid sarcoma: Incidentally, middle-aged male patients with MS tend to develop a progressive form of MS, which is nonremitting, IFN-β insensitive, and associated with more significant CNS neuronal damage than relapsing–remitting MS (65, 66).